140 related articles for article (PubMed ID: 31272570)
1. TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma.
Damento GM; Pulido JS; Abbott BA; Hodge DO; Dalvin LA
Mayo Clin Proc; 2019 Jul; 94(7):1287-1295. PubMed ID: 31272570
[TBL] [Abstract][Full Text] [Related]
2. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.
Damento G; Kavoussi SC; Materin MA; Salomão DR; Quiram PA; Balasubramaniam S; Pulido JS
Mayo Clin Proc; 2014 Nov; 89(11):1481-6. PubMed ID: 25444484
[TBL] [Abstract][Full Text] [Related]
3. [Connection between uveal melanoma and dysplastic naevus syndrome].
Hammer H; Tóth-Molnár E; Oláh J; Dobozy A
Magy Onkol; 2005; 49(1):15-8. PubMed ID: 15902328
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate Exposure and Risk of Cutaneous Malignant Melanoma: No Evidence of a Dose-response Relationship.
Polesie S; Gillstedt M; Paoli J; Osmancevic A
Acta Derm Venereol; 2018 Oct; 98(9):888-895. PubMed ID: 29972216
[TBL] [Abstract][Full Text] [Related]
5. Uveal melanoma: a study on incidence of additional cancers in the Swedish population.
Bergman L; Nilsson B; Ragnarsson-Olding B; Seregard S
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):72-7. PubMed ID: 16384946
[TBL] [Abstract][Full Text] [Related]
6. Relationship of uveal and cutaneous malignant melanoma in persons with multiple primary tumors.
Shors AR; Iwamoto S; Doody DR; Weiss NS
Int J Cancer; 2002 Nov; 102(3):266-8. PubMed ID: 12397648
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α blockade and development of uveal melanoma: expected adverse effect or just coincidence?
Sato T
Mayo Clin Proc; 2014 Nov; 89(11):1467-70. PubMed ID: 25444483
[No Abstract] [Full Text] [Related]
8. Pesticide exposure in farming and forestry and the risk of uveal melanoma.
Behrens T; Lynge E; Cree I; Lutz JM; Eriksson M; Guénel P; Merletti F; Morales-Suarez-Varela M; Afonso N; Stengrevics A; Févotte J; Sabroe S; Llopis-González A; Gorini G; Hardell L; Stang A; Ahrens W
Cancer Causes Control; 2012 Jan; 23(1):141-51. PubMed ID: 22052342
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous dysplastic naevi: risk factor for uveal melanoma.
Hammer H; Tóth-Molńar E; Oláh J; Dobozy A
Lancet; 1995 Jul; 346(8969):255-6. PubMed ID: 7616832
[No Abstract] [Full Text] [Related]
10. Are atypical nevi a risk factor for uveal melanoma? A case-control study.
van Hees CL; de Boer A; Jager MJ; Bleeker JC; Kakebeeke HM; Crijns MB; Vandenbroucke JP; Bergman W
J Invest Dermatol; 1994 Aug; 103(2):202-5. PubMed ID: 8040610
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous dysplastic naevi in uveal melanoma patients: markers for prognosis?
Tóth-Molnár E; Hammer H; Oláh J
Melanoma Res; 2000 Feb; 10(1):36-9. PubMed ID: 10711638
[TBL] [Abstract][Full Text] [Related]
12. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
13. Increasing Incidence of Melanoma in the Elderly: An Epidemiological Study in Olmsted County, Minnesota.
Olazagasti Lourido JM; Ma JE; Lohse CM; Brewer JD
Mayo Clin Proc; 2016 Nov; 91(11):1555-1562. PubMed ID: 27692970
[TBL] [Abstract][Full Text] [Related]
14. The risk of other primary cancer in patients with uveal melanoma: a retrospective cohort study of a Canadian population.
Callejo SA; Al-Khalifa S; Ozdal PC; Edelstein C; Burnier MN
Can J Ophthalmol; 2004 Jun; 39(4):397-402. PubMed ID: 15327105
[TBL] [Abstract][Full Text] [Related]
15. Other cancers in uveal melanoma patients and their families.
Turner BJ; Siatkowski RM; Augsburger JJ; Shields JA; Lustbader E; Mastrangelo MJ
Am J Ophthalmol; 1989 Jun; 107(6):601-8. PubMed ID: 2729409
[TBL] [Abstract][Full Text] [Related]
16. Host factors, UV radiation, and risk of uveal melanoma. A case-control study.
Seddon JM; Gragoudas ES; Glynn RJ; Egan KM; Albert DM; Blitzer PH
Arch Ophthalmol; 1990 Sep; 108(9):1274-80. PubMed ID: 2400347
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prior primary malignancy as a determinant of uveal melanoma. A case-control study.
Lischko AM; Seddon JM; Gragoudas ES; Egan KM; Glynn RJ
Ophthalmology; 1989 Dec; 96(12):1716-21. PubMed ID: 2622616
[TBL] [Abstract][Full Text] [Related]
18. Ocular melanoma: epidemiology, clinical presentation and relationship with dysplastic nevi.
Richtig E; Langmann G; Müllner K; Smolle J
Ophthalmologica; 2004; 218(2):111-4. PubMed ID: 15004500
[TBL] [Abstract][Full Text] [Related]
19. No excess prior cancer in patients with uveal melanoma.
Holly EA; Aston DA; Ahn DK; Kristiansen JJ; Char DH
Ophthalmology; 1991 May; 98(5):608-11. PubMed ID: 2062491
[TBL] [Abstract][Full Text] [Related]
20. Dysplastic nevi are a risk factor for uveal melanoma.
Hammer H; Oláh J; Tóth-Molnár E
Eur J Ophthalmol; 1996; 6(4):472-4. PubMed ID: 8997595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
